指南与共识骨软组织肉瘤与黑色素瘤

软组织肉瘤患者管理中的争议:2022年肉瘤科学现状会议建议

Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.
指南 / 共识 · Eur J Cancer · 2022-11-16

2022年5月首届肉瘤科学现状共识会议采用改良德尔菲法,由62名欧洲肉瘤专家对软组织肉瘤诊疗争议问题进行投票,识别出16项强共识(≥95%)条目和30项≥75%共识条目,但许多争议话题仍未达成共识,会议还提出了未来科学问题与临床试验优先方向。

要点

  • 62名欧洲肉瘤专家参与投票,识别出16项强共识(≥95%)条目。
  • 另有30项诊断和治疗问题达到≥75%共识。
  • 许多争议话题仍未达成共识,会议提出未来研究优先方向。

核心结论

  • 会议总结了投票结果与讨论,识别出16项强共识(≥95%)条目和30项≥75%共识条目,但许多争议话题仍未达成共识。
  • 会议提出了未来科学问题、临床试验优先事项、登记注册、质量保证及利益相关方行动建议。

研究设计与样本

  • 采用改良德尔菲法,在2022年5月首届肉瘤科学现状共识会议(CSSS)前对软组织肉瘤关键问题与争议进行投票。
  • 62名欧洲肉瘤专家参与了调查。

主要发现

  • 专家识别出16项强共识(≥95%)条目。
  • 另有30项诊断和治疗问题达到≥75%共识。
  • 许多争议话题仍未达成共识。

关键数值与推荐

  • 强共识定义为共识度≥95%,共16项。
  • 共识度≥75%的条目共30项,涉及诊断和治疗问题。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence. METHODS: During the first Consensus Conference on the State of Science in Sarcoma (CSSS), we used a modified Delphi process to identify areas of controversy in the field of sarcoma, to name topics with limited evidence-based data in which a scientific and knowledge gap may remain and a consensus statement will help to guide patient management. We determined scientific questions which need to be addressed in the future in order to generate evidence and to inform physicians and caregivers in daily clinical practice in order to improve the outcomes of patients with sarcoma. We conducted a vote on STS key questions and controversies prior to the CSSS meeting, which took place in May 2022. RESULTS: Sixty-two European sarcoma experts participated in the survey. Sixteen strong consensus (≥95%) items were identified by the experts, as well as 30 items with a ≥75% consensus on diagnostic and therapeutic questions. Ultimately, many controversy topics remained without consensus. CONCLUSIONS: In this manuscript, we summarise the voting results and the discussion during the CSSS meeting. Future scientific questions, priorities for clinical trials, registries, quality assurance, and action by stakeholders are proposed. Platforms and partnerships can support innovative approaches to improve management and clinical research in STS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rothermundt C, Andreou D, Blay JY, et al. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. Eur J Cancer. 2022. PMID: 36599184. doi:10.1016/j.ejca.2022.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。